A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

Name: A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
License: Public Domain

GlobeImmune

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

nsclc

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 435749
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.